Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
0.4907 -0.0093 (-1.86%) 11:49 ET [NASDAQ]
0.4911 x 600 0.4968 x 100
Realtime by (Cboe BZX)
0.4911 x 600 0.4968 x 100
Realtime 0.5190 +0.0187 (-) 09:28 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.4800
Day High
0.5200
Open 0.5100
Previous Close 0.5000 0.5000
Volume 265,327 265,327
Avg Vol 1,161,863 1,161,863
Stochastic %K 29.55% 29.55%
Weighted Alpha -78.61 -78.61
5-Day Change -0.0466 (-8.58%) -0.0466 (-8.58%)
52-Week Range 0.4000 - 5.8500 0.4000 - 5.8500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,074
  • Shares Outstanding, K 80,100
  • Annual Sales, $ 138,100 K
  • Annual Income, $ 31,870 K
  • EBIT $ 25 M
  • EBITDA $ 21 M
  • 60-Month Beta 1.34
  • Price/Sales 0.26
  • Price/Cash Flow 1.26
  • Price/Book N/A
  • Price/Earnings ttm 1.20
  • Earnings Per Share ttm 0.38
  • Most Recent Earnings $0.22 on 03/06/25
  • Next Earnings Date 05/14/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 310.63% ( -73.16%)
  • Historical Volatility 99.22%
  • IV Percentile 85%
  • IV Rank 40.78%
  • IV High 739.39% on 04/22/24
  • IV Low 15.34% on 09/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 92
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 6,269
  • Open Int (30-Day) 6,300

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.10
  • Number of Estimates 4
  • High Estimate 0.21
  • Low Estimate -0.08
  • Prior Year 0.17
  • Growth Rate Est. (year over year) -41.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4000 +24.13%
on 04/07/25
Period Open: 0.6697
0.6931 -28.37%
on 03/20/25
-0.1732 (-25.86%)
since 03/10/25
3-Month
0.4000 +24.13%
on 04/07/25
Period Open: 0.8801
0.9800 -49.34%
on 02/06/25
-0.3836 (-43.59%)
since 01/10/25
52-Week
0.4000 +24.13%
on 04/07/25
Period Open: 2.1000
5.8500 -91.51%
on 05/01/24
-1.6035 (-76.36%)
since 04/10/24

Most Recent Stories

More News
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

Shares of Valneva VALN rose 12% on Wednesday after the company announced that it has vaccinated the first participant in a phase II study evaluating its investigational Shigella vaccine, Shigella4V2 (S4V2).This...

CTMX : 0.4907 (-1.92%)
ETNB : 4.85 (-12.45%)
VALN : 6.30 (-7.02%)
ANIP : 63.19 (-4.27%)
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug

Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational CRISPR-based allogeneic CAR-T therapy, ALLO-329.These designations apply to three autoimmune...

ALLO : 1.3950 (-1.76%)
CTMX : 0.4907 (-1.92%)
ETNB : 4.85 (-12.45%)
ANIP : 63.19 (-4.27%)
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Akebia Therapeutics AKBA recently announced that it is floating a secondary issue of 25 million shares of its common stock to the public at an issue price of $2 per share, amounting to $50 million.The...

CTMX : 0.4907 (-1.92%)
ETNB : 4.85 (-12.45%)
AKBA : 1.6000 (-5.88%)
ANIP : 63.19 (-4.27%)
Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on its lead pipeline drug EO-3021 for treating advanced, unresectable or metastatic...

CTMX : 0.4907 (-1.92%)
ETNB : 4.85 (-12.45%)
ELEV : 0.2583 (-0.65%)
ANIP : 63.19 (-4.27%)
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

Allogene Therapeutics ALLO incurred a loss of 28 cents per share in fourth-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 34 cents. In the year-ago period, the company had incurred...

ALLO : 1.3950 (-1.76%)
CTMX : 0.4907 (-1.92%)
ETNB : 4.85 (-12.45%)
ANIP : 63.19 (-4.27%)
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

CTMX : 0.4907 (-1.92%)
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

CTMX : 0.4907 (-1.92%)
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

CTMX : 0.4907 (-1.92%)
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive...

CTMX : 0.4907 (-1.92%)
VYGR : 2.95 (-5.14%)
CSTL : 19.08 (-5.12%)
STOK : 6.08 (-5.44%)
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Shares of Mirum Pharmaceuticals MIRM were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024,...

CTMX : 0.4907 (-1.92%)
MIRM : 37.78 (-8.90%)
VYGR : 2.95 (-5.14%)
CSTL : 19.08 (-5.12%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.6269
2nd Resistance Point 0.5734
1st Resistance Point 0.5369
Last Price 0.4907
1st Support Level 0.4469
2nd Support Level 0.3934
3rd Support Level 0.3569

See More

52-Week High 5.8500
Fibonacci 61.8% 3.7681
Fibonacci 50% 3.1250
Fibonacci 38.2% 2.4819
Last Price 0.4907
52-Week Low 0.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar